GENE ONLINE|News &
Opinion
Blog

2023-12-05| Asia-Pacific

PRISM BioLab and Eli Lilly Join Forces in Revolutionary Drug Discovery Collaboration

by Sinead Huang
Share To

PRISM BioLab, a Japanese biotechnology company, has officially entered into a transformative License and Collaboration Agreement with Eli Lilly and Company (Lilly). The collaboration’s primary focus is the discovery of oral inhibitors for protein-protein interaction (PPI) targets. Leveraging PRISM BioLab’s cutting-edge PepMetics® technology, the partnership aims to revolutionize drug discovery by addressing previously undruggable PPIs. 

Related article: Roche Looks for Peptide-Like Small Molecules with Prism BioLab, joining Merck, Eisai and Boehringer Ingelheim

The Power of PepMetics®: Propelling Drug Discovery Forward

Under the terms of the agreement, PRISM and Lilly will work hand-in-hand to explore small molecule inhibitors targeting a PPI selected by Lilly. The collaboration allows Lilly the flexibility to include up to two additional targets, with full responsibility for the clinical development and commercialization of resulting products. PRISM BioLab stands to receive upfront payments and could potentially earn up to $660 million in preclinical, clinical, and commercial development milestone payments. Additionally, royalties on product sales further underline the commitment to fruitful collaboration.

Expressing enthusiasm for the collaboration, Dai Takehara, President and CEO of PRISM BioLab, emphasized the potential to reshape drug discovery paradigms. The PepMetics® technology holds the promise of transforming previously undruggable PPIs into accessible targets for small molecules. Collaborating with Lilly, a global pharmaceutical innovator, signifies a crucial step towards expanding the scope of druggable targets, ultimately benefiting patients facing various diseases.

PRISM BioLab’s Commitment and Promising Technology

Located at Shonan iPark, Fujisawa, Kanagawa, PRISM BioLab stands out as a biotechnology trailblazer, utilizing the proprietary PepMetics® technology to develop small molecule inhibitors for PPI targets. The technology, featuring a unique class of molecules mimicking three-dimensional structures, holds potential applications in cancer, autoimmune diseases, fibrosis, and more. Current collaborations with pharmaceutical giants and clinical developments underscore the transformative power of PepMetics®, promising a paradigm shift in the field of drug discovery.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
LATEST
Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells
2024-07-12
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
2024-07-12
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
2024-07-12
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
2024-07-12
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
2024-07-11
Delivering Affordable Biologic Medicines Worldwide: An Interview with Tanvex Chairman and CEO, Henry Chen
2024-07-11
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
2024-07-11
EVENT
Scroll to Top